Alkem Laboratories Limited has entered into an Amendment cum Supplemental Agreement dated 13th February, 2026 with its subsidiary Enzene Biosciences Limited and key investors. The agreement involves Eight Roads Ventures India Healthcare IV, L.P., F-Prime Capital Partners Life Sciences Fund VI LP, and ERVI Healthcare IV Holdings Limited for strategic fund infusion and governance amendments.

Agreement Structure and Fund Infusion

The Amendment cum Supplemental Agreement facilitates three key objectives: the allotment of securities by Enzene to F-Prime Capital and ERVI Healthcare on a preferential basis through private placement, adherence by ERVI Healthcare to the existing Shareholders' Agreement terms, and amendment of certain provisions of the original Shareholders' Agreement.

Securities Allocation Details

Under the preferential allotment arrangement, F-Prime Capital will subscribe to 1,30,451 Series B Compulsorily Convertible Preference Shares, while ERVI Healthcare will acquire 4,27,851 Series B CCPS along with 10 equity shares. Each security carries a face value of Rs. 10.00 and is priced at Rs. 468.60, including a premium of Rs. 458.60 per share.

Post-Allotment Shareholding Structure

Following the completion of the preferential allotment, the shareholding pattern in Enzene Biosciences will be restructured on a fully diluted basis:

Regulatory Compliance and Background

This disclosure follows Alkem's earlier intimations dated 23rd December, 2022 regarding the original Shareholders' Agreement and 11th August, 2023 concerning liability creation. The current amendment ensures ERVI Healthcare's adherence to the Shareholders' Agreement terms while facilitating the strategic investment in Enzene Biosciences.

Strategic Implications

The agreement maintains Alkem's controlling stake in its subsidiary Enzene Biosciences at 88.99% while bringing in additional capital and strategic partnerships. The transaction does not fall within related party transaction purview and has no impact on Alkem's management or control structure. The fund infusion strengthens Enzene's financial position for its biosciences operations and growth initiatives.

Alkem Laboratories has announced its Q3FY26 financial results, delivering robust performance with 11% revenue growth and declaring an interim dividend of ₹43 per share. The pharmaceutical company also revealed a strategic acquisition in the medical devices sector through its subsidiary Alkem MedTech.

Q3FY26 Financial Performance

The company delivered strong financial metrics across key parameters for the quarter ended December 31, 2025:

R&D expenses for the quarter stood at ₹1,390 million, representing 3.7% of total revenue from operations compared to 3.9% in Q3FY25.

Business Segment Performance

Alkem's diversified revenue streams showed varied growth patterns across geographies:

According to IQVIA data, the company registered 9.8% growth compared to the Indian Pharmaceutical Market growth of 10.9%. Alkem outperformed in the acute segment by 80 basis points and marginally outperformed in chronic category by 18 basis points.

Strategic Acquisition Announcement

Alkem announced the execution of a binding term sheet to acquire a majority stake in Occlutech Holding AG, a Switzerland-based global medical devices company specializing in minimally invasive cardiac implants. The acquisition will be made through Alkem's wholly-owned subsidiary Alkem MedTech.

Sandeep Singh, Managing Director, commented: "This acquisition holds strategic importance as we work towards establishing a global footprint in medical devices. Occlutech is the third-largest player globally in the minimally invasive cardiac implants segment."

Interim Dividend Declaration

The Board of Directors declared an interim dividend of ₹43 per equity share for financial year 2025-2026:

Exceptional Items Impact

The company reported exceptional items of ₹528 million for the quarter, primarily related to the Government of India's notification of four Labour Codes effective from November 21, 2025. This represents a preliminary assessment of the incremental impact based on available information.

Management Commentary

Dr. Vikas Gupta, CEO, expressed optimism about future prospects: "Looking ahead, the planned launch of our GLP-1 semaglutide in March 2026 is expected to be among our key growth drivers. Our focus remains on execution, strengthening our product portfolio, and building long-term competitiveness across markets."